Retension Pharmaceuticals Reports Q3 GAAP EPS of -$7.33 and Announces IPO Proceeds

Retension Pharmaceuticals reported a GAAP earnings per share (EPS) of -$7.33 for the third quarter ending September 30, 2026. The company's cash and cash equivalents stood at $9.2 million at the end of the quarter, down from $18.9 million at the end of 2025. Following a recent initial public offering (IPO) that closed after the quarter-end, the company significantly bolstered its liquidity position. Including approximately $45.1 million in net IPO proceeds, Retension's pro forma cash and cash equivalents rose to approximately $54.3 million. The IPO was upsized with shares priced at $12 per share.

2 articles from 2 sources · updated

Coverage